Home
°øÁö»çÇ×
CSL ¾Ù¹ü
¹«·á À̸ÞÀÏ @cell-signaling °èÁ¤ ¸¸µé±â

Designed
    by Heidi-Dream

 

´ë»çÁõÈıº ¹× ¼¼Æ÷ ½ÅÈ£Àü´Þ ¿¬±¸½Ç
(Matabolic Syndrome and Cell Signaling Laboratory)

 

 

¡á  Home > °øÁö»çÇ×

2014³â "±Û·Î¹ú ¸ÞµðÄ® µð½ºÄ¿¹ö¸®"¿¡ ¼±Á¤µÇ¾ú½À´Ï´Ù
 cell  03-18
À̹ø ¿¬±¸¼º°ú´Â ¼¼Æ÷»ý¹°ÇÐºÐ¾ß ±¹Á¦ÇмúÁöÀÎ ¡®¼¼Æ÷½ÅÈ£Àü´Þ (Cellular Signalling)¡¯ÀÇ 2¿ùÈ£¿¡ °ÔÀçµÇ¾úÀ¸¸ç, »õ·Î¿î ¾ËÄÚ¿Ã ÀÇÁ¸¼º Áö¹æ°£ Ä¡·áÁ¦·Î¼­ÀÇ °¡´É¼ºÀÌ ÀÎÁ¤µÇ¾î ½Å¾à »ó¾÷È­ ¹× ½Å¾àÈĺ¸ ¹ß±¼À» ¸ñÀûÀ¸·Î ¼³¸³µÈ ±¹Á¦Àû ´ÜüÀÎ ¡®±Û·Î¹ú ¸ÞµðÄ® µð½ºÄ¿¹ö¸®¡¯ÀÇ ½Å¾à°³¹ßºÐ¾ß (4¿ù È£)¿¡µµ ¼±Á¤µÆ´Ù.


From: Dr. David Levy <david.levy@globalmedicaldiscovery.com>
Date: Mon, Mar 17, 2014 at 9:21 PM
Subject: {Beta}-Lapachone alleviates alcoholic fatty liver disease in rats
To: insulin@cnu.ac.kr


Dear Dr. Park,

We are pleased to let you know that our Target Selection Team at Global Medical Discovery has identified your recent publication: {Beta}-Lapachone alleviates alcoholic fatty liver disease in rats as a Key Scientific Article contributing to excellence in biomedical research. We would therefore like to feature it in our next edition of Global Medical Discovery Series.

Global Medical Discovery alerts the scientific, clinical and industrial community to innovative papers dedicated to investigating causes and discovering cures for major diseases and debilitating illnesses  (for this week edition, click here). Global Medical Discovery is viewed almost 585,000 times each month by our audience of academic, clinical and industrial R&D Scientists and it is featured on the intranets of a growing number of the top 50 Biotechnology and Pharmaceutical companies as well as major academic institutions.

Papers featured by Global Medical Discovery [ISSN 1929-8536] gain extensive exposure. This is good for us since our initial aim was to establish an environment that helps advance medical discovery and accelerate drug development. We also believe that high quality creative research deserves recognition and perhaps more importantly, exposure through Global Medical Discovery is therefore also good for you and your organization since this provides a showcase for key studies such as yours. This exposure has the added benefit of encouraging industrial funding and licensing.

Please do take the time to explore best papers featured at Global Medical Discovery based on the quality of research and its potential impact: http://globalmedicaldiscovery.com.  Please don¡¯t hesitate to contact me if you need any further information.

Respectfully,
David Levy, PhD EMBA
VP Scientific affairs, Global Medical Discovery Ltd
Ottawa, K4A 3X8,  Ontario, Canada
Tel (+1) 613 878 3745
Email: David.Levy@GlobalMedicalDiscovery.Com
Web: http://globalmedicaldiscovery.com
=======================================================
CONFIDENTIALITY NOTICE
This communication, and the information that it contains: (a) is intended for the person(s) or organization(s) named above or their agents and for no other person or organization and (b) may be confidential, legally privileged and protected by law. Unauthorized use, copying or disclosure of any of it may be unlawful. If you have received this communication in error, please contact us immediately by email, telephone or facsimile.

 LIST   
  43   YTN science¿¡¼­ "S6K1" ¿¬±¸°á°ú º¸µµ  cell 12-10  
  42   ¹ÚÁö¼ö¹Ú»ç´Ô°ú ±³¼ö´Ô ³í¹®ÀÌ ÃÖÁ¾ Cell signaling¿¡ Accept µÇ¾ú½À´Ï´Ù  cell 09-16  
  41   ÀÌÇöÁö ÇлýÀÇ ³í¹®ÀÌ ÃâÆÇ µÇ¾ú½À´Ï´Ù  cell 08-01  
  40   Quangdon ÇлýÀÇ ³í¹®ÀÌ ÃâÆÇ µÇ¾ú½À´Ï´Ù  cell 07-30  
  39   Liu Meiyou ÇлýÀÇ ³í¹®ÀÌ IJMM¿¡ µåµð¾î publish µÇ¾ú½À´Ï´Ù  cell 09-01  
  38   ¹ÚÁö¼ö ¹Ú»ç´ÔÀÌ 2015 ASIATOX ¿¡¼­ Pfizer »óÀ» ¹Þ¾Ò¾î¿ä.  cell 07-19  
  37   »õ·Î ÇÕ·ùÇÑ ·ùÁ¦±¤/ÀÌÇöÁö ¼®»çÇлýÀ» ȯ¿µ ÇÕ´Ï´Ù  cell 06-14  
  36   RobinÀÌ ¼®»ç ÇÐÀ§ ³í¹®½É»ç¸¦ Àß ¸¶ÃƽÀ´Ï´Ù  cell 06-02  
  35   ÃÖ±Ù¿¡ ÇÕ·ùÇÑ ÀÌ¿ëÁø ¹Ú»ç´ÔÀ» ȯ¿µÇÕ´Ï´Ù  cell 04-28  
  34   ±³¼ö´ÔÀÌ YTN science¿¡ ÀüÈ­ÀÎÅͺ並 Çϼ̾î¿ä ^^*  cell 04-27  
    2014³â "±Û·Î¹ú ¸ÞµðÄ® µð½ºÄ¿¹ö¸®"¿¡ ¼±Á¤µÇ¾ú½À´Ï´Ù  cell 03-18  
  32   ¹Ú·æÁø ¼±»ý´Ô°ú ¹ÚÁö¼ö ¼±»ý´ÔÀÇ ³í¹®ÀÌ Accept µÇ¾ú½À´Ï´Ù  cell 12-26  
  31   ½Å»óÈñ ¼±»ý´Ô°ú ¹ÚÁö¼ö ¼±»ý´ÔÀÇ ³í¹®ÀÌ Accept µÇ¾ú½À´Ï´Ù  cell 11-19  
  30   ¹ÚÁö¼ö ¼±»ý´Ô 4¹øÂ° ³í¹®ÀÌ Accept µÇ¾ú½À´Ï´Ù  cell 11-13  
  29   ¹ÚÁö¼ö ¼±»ý´ÔÀÇ PDK1-Ab ³í¹®ÀÌ Life Sciences ¿¡ Accept µÇ¾ú½À´Ï´Ù  cell 09-17  
  28   ¹ÚÁö¼ö ¼±»ý´Ô 3¹øÂ° ³í¹®ÀÌ Brain Research ¿¡ Accept µÇ¾ú½À´Ï´Ù  cell 08-16  
  27   PHF20/NF-kB ¿¬±¸³í¹®ÀÌ Nature Communication¿¡ Accept µÇ¾ú½À´Ï´Ù  cell 07-01  
  26   ÀÌ¿Á¹®¹Ú»ç¿Í ¹ÚÁö¼öÇлýÀÇ 1¹øÂ° ³í¹®ÀÌ Cellular Signaling¿¡ äÅõǾú½À´Ï´Ù  cell 09-17  
  25   2012³â À»¹Ì³â Èæ·æÀÇ ÇØ°¡ ¹à¾Ò½À´Ï´Ù  cell 01-24  
  24   ¿¬±¸½ÇÀÇ ÁÁÀº ÀϵéÀ» ÃàÇÏÇÕ´Ï´Ù  cell 09-13  
[1] 2 [3][4]   SEARCH
Copyright 1999-2026 Zeroboard / skin by GGAMBO

 

 


Matabolic Syndrome and Cell Signaling Laboratory in Institute for Cancer Research
Department of Pharmacology, College of Medicine, Chungnam National University
266 Munhwa-ro, Jung-gu, Daejeon, 35015, South Korea
Tel: +82-42-280-6768 Fax: +82-42-585-6627
COPYRIGHT ¨Ï 2009 Metabolic Syndrome and Cell Signaling Laboratory, ALL RIGHTS RESERVED.